

Tom Lesluyes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8259125/publications.pdf>

Version: 2024-02-01

39
papers

1,126
citations

394421

19
h-index

454955

30
g-index

41
all docs

41
docs citations

41
times ranked

1450
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of copy number alterations in human cancer. <i>Nature</i> , 2022, 606, 984-991.	27.8	154
2	A pan-cancer compendium of chromosomal instability. <i>Nature</i> , 2022, 606, 976-983.	27.8	111
3	RNA sequencing validation of the Complexity INdex in SARComas prognostic signature. <i>European Journal of Cancer</i> , 2016, 57, 104-111.	2.8	66
4	Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum. <i>American Journal of Surgical Pathology</i> , 2019, 43, 747-754.	3.7	65
5	Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. <i>Modern Pathology</i> , 2018, 31, 1683-1693.	5.5	56
6	An integrative analysis of the age-associated multi-omic landscape across cancers. <i>Nature Communications</i> , 2021, 12, 2345.	12.8	54
7	Genome-wide <i>in silico</i> prediction of gene expression. <i>Bioinformatics</i> , 2012, 28, 2789-2796.	4.1	50
8	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. <i>Modern Pathology</i> , 2018, 31, 816-828.	5.5	46
9	Recurrent <i>TRIO</i> Fusion in Nontranslocation-Related Sarcomas. <i>Clinical Cancer Research</i> , 2017, 23, 857-867.	7.0	41
10	Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. <i>Oncolmmunology</i> , 2020, 9, 1792036.	4.6	31
11	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 1787-1797.	6.4	30
12	Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas. <i>Annals of Oncology</i> , 2018, 29, 1828-1835.	1.2	30
13	<i>GREB1</i> - <i>CTNNB1</i> fusion transcript detected by RNA-seq in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel <i>CTNNB1</i> rearrangement. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 155-163.	2.8	30
14	Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas. <i>Modern Pathology</i> , 2019, 32, 1786-1794.	5.5	25
15	The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. <i>Scientific Reports</i> , 2017, 7, 5480.	3.3	24
16	Vnn1 pantetheinase limits the Warburg effect and sarcoma growth by rescuing mitochondrial activity. <i>Life Science Alliance</i> , 2018, 1, e201800073.	2.8	24
17	Differential motif enrichment analysis of paired ChIP-seq experiments. <i>BMC Genomics</i> , 2014, 15, 752.	2.8	23
18	Fusion-mediated chromosomal instability promotes aneuploidy patterns that resemble human tumors. <i>Oncogene</i> , 2019, 38, 6083-6094.	5.9	23

#	ARTICLE	IF	CITATIONS
19	CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 124-129.	2.8	23
20	Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements. <i>Cell Cycle</i> , 2018, 17, 605-615.	2.6	21
21	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5746-E5755.	7.1	20
22	The Role of the Anti-Aging Protein Klotho in IGF-1 Signaling and Reticular Calcium Leak: Impact on the Chemosensitivity of Dedifferentiated Liposarcomas. <i>Cancers</i> , 2018, 10, 439.	3.7	19
23	Genome remodeling upon mesenchymal tumor cell fusion contributes to tumor progression and metastatic spread. <i>Oncogene</i> , 2020, 39, 4198-4211.	5.9	19
24	Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells. <i>Oncotarget</i> , 2017, 8, 16669-16689.	1.8	15
25	Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas. <i>Cancers</i> , 2019, 11, 922.	3.7	13
26	The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 855-861.	7.0	13
27	Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. <i>PLoS ONE</i> , 2015, 10, e0137794.	2.5	12
28	LIX1 regulates YAP activity and controls gastrointestinal cancer cell plasticity. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9244-9254.	3.6	11
29	ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. <i>Cancers</i> , 2021, 13, 2151.	3.7	10
30	Cell-cell fusion of mesenchymal cells with distinct differentiations triggers genomic and transcriptomic remodelling toward tumour aggressiveness. <i>Scientific Reports</i> , 2020, 10, 21634.	3.3	9
31	Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances. <i>Annals of Oncology</i> , 2019, 30, 153-155.	1.2	8
32	A Global and Integrated Analysis of CINSARC-Associated Genetic Defects. <i>Cancer Research</i> , 2020, 80, 5282-5290.	0.9	8
33	Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. <i>ESMO Open</i> , 2021, 6, 100037.	4.5	8
34	Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHiC-STS trial. <i>BMC Cancer</i> , 2020, 20, 716.	2.6	7
35	CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. <i>Cancer Medicine</i> , 2023, 12, 1350-1357.	2.8	7
36	Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion. <i>Cancers</i> , 2020, 12, 1281.	3.7	4

#	ARTICLE	IF	CITATIONS
37	RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas. <i>Cancers</i> , 2019, 11, 81.	3.7	3
38	E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. <i>Oncogene</i> , 2021, 40, 5567-5578.	5.9	3
39	Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from aPhaseA1 trial of the German Interdisciplinary Sarcoma Group (GISG 03). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 280-285.	2.0	1